BAXTER'S NOVACOR LVAS AS ALTERNATIVE TO HEART TRANSPLANTATION
This article was originally published in The Gray Sheet
BAXTER'S NOVACOR LVAS AS ALTERNATIVE TO HEART TRANSPLANTATION underwent its first placement, in an English patient on Aug. 24. The implantation marks the first time that the left ventricular assist system will be evaluated as "a long-term treatment for end-stage heart failure," Baxter says. The study, in cooperation with Papworth Hospital NHS Trust of Cambridge University, is designed as a pilot program of four participants. Twenty-five patients ultimately will be enrolled. The LVAS was developed by Baxter's Novacor division.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.